Διαχρονική εξέλιξη των νεότερων αντιδιαβητικών φαρμάκων και της φαρμακευτικής τους δαπάνης : προτάσεις για την εδραίωση τους στην φαρμακευτική αγορά
Evolution of newer antidiabetic drugs and their pharmaceutical expenditure : proposals for their establishment in the pharmaceutical market
View/ Open
Keywords
Διαβήτης ; Νεότερα αντιδιαβητικά φάρμακα ; Θεραπευτική αντιμετώπιση ; Φαρμακευτική δαπάνη ; Ασφαλιστική τιμή ; Συμμετοχή ασθενών ; Λιανική τιμή ; Επαγγελματίες υγείας ; Ασθενείς ; Rebate ; ClawbackAbstract
This thesis investigates the evolution of the newer antidiabetic drugs and the pharmaceutical expenditure with which they are associated. The first chapter focuses on the definition and classification of diabetes, providing thorough analysis of disease demographics and predictions of the disease at both global and national levels.
Then, the therapeutic management of diabetes is examined, approaching various categories of drugs such as biguanides, sulfonylureas, meglitinides, as well as the newer antidiabetic drugs, examining their advantages and disadvantages. Afterwards, the economic impact of the disease on a global and Greek level is analyzed. The fourth chapter focuses on pharmaceutical expenditure, analyzing medication costs of
diabetes. The fifth chapter presents the evolution over time of the newest antidiabetic drugs and examines their impact on the pharmaceutical market. In the sixth chapter, the factors affecting pharmaceutical expenditure are explored, including the pricing and repricing regulations of medicines in Greece.
The seventh chapter includes the methodology and the eighth the results of the research questionnaire, which was developed in order to investigate the perspective of pharmacists in the establishment of the newer antidiabetic drugs. Finally, the conclusions and some proposals for the establishment of the newest antidiabetic drugs in the pharmaceutical market are presented.